Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells

Liver International

Volumn 29, Issue 3, 2009, Pages 366-373

  Bonifaz, Vania ^a   Shan, Ying ^a   Lambrecht, Richard W ^a   Donohue, Susan E ^a   Moschenross, Darcy ^a   Bonkovsky, Herbert L ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Bach1; Haem oxygenase 1; Hepatitis C; Interferon; Silymarin

Indexed keywords

ERYTHROID RELATED FACTOR 2; HEME OXYGENASE 1; INTERFERON; JANUS KINASE; MESSENGER RNA; NONSTRUCTURAL PROTEIN 5A; NUCLEAR FACTOR; PROTEIN TYROSINE KINASE; SILYMARIN; UNCLASSIFIED DRUG;

ARTICLE; CELL PROTECTION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; GENE EXPRESSION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE (DECYCLIZING); HEPACIVIRUS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SILYMARIN; TETRAZOLIUM SALTS; THIAZOLES;

EID: 59849105278     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01833.x     Document Type: Article

References (43)

1. Collier L, Oxford J. Human Virology. Oxford, UK: Oxford University Press, 2006.
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-62.
3. Hjikata M, Mizushima H, Tanji Y, et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci USA 1993; 90: 10773-7.
4. Lohmann V, Koch JO, Bartenschlager R. Processing pathways of the hepatitis C virus proteins. J Hepatol 1996; 24: 11-9.
5. Major ME, Feinstone SM. The molecular virology of hepatitis C. Hepatology 1997; 25: 1527-38.
6. Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nature Clin Pract 2007; 4: 622-34.
7. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
8. Korenaga M, Wang T, Li Y, et al. Hepatitis C Virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8.
9. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-604.
10. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-55.
11. Tenhunen R, Marver HS, Schmid R. Microsomal heme oxygenase. Characterization of the enzyme. J Biol Chem 1969; 244: 6388-94.
12. Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-22.
13. Motohashi H, Shavit JA, Igarashi K, Yamamoto M, Engel JD. The world according to Maf. Nucleic Acids Res 1997; 25: 2953-9.
14. Shan Y, Lambrecht R, Donohue S, Bonkovsky H. Role of Bach1 and Nrf2 in up-regulation of the heme oxygenase-1 gene by cobalt protoporphyrin. FASEB J 2006; 20: E2258-67.
15. Ghaziani T, Shan Y, Lambrecht R, et al. HCV proteins increase expression of heme oxygenase-1 (HO-1) and decrease expression of Bach1 in human hepatoma cells. J Hepatol 2006; 45: 1-8.
16. Shan Y, Lambrecht RW, Ghaziani T, Donohue SE, Bonkovsky HL. Role of Bach-1 in regulation of heme oxygenase-1 in human liver cells: Insights from studies with small interfering RNAs. J Biol Chem 2004; 279: 51769-74.
17. McHutchison JG, Fried MW. Current therapy for hepatitis C: Pegylated interferon and ribavirin. Clin Liv Dis 2003; 7: 149-61.
18. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
19. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47: 605-12.
20. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol 1983; 32: 1141-8.
21. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994; 27: 105-12.
22. Masini A, Ceccarelli D, Giovannini F, Montosi G, Garuti C, Pietrangelo A. Iron induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin. J Bioenerg Biomembr 2000; 32: 174-82.
23. Polyak S, Morishima C, Shuhart M, Wang C, Liu Y, Lee D. Inhibition of T cell inflammatory cytokines, hepatocyte NF-kB signaling, and HCV infection by standardized silymarin. Gastroenterology 2007; 132: 1925-36.
24. Scherzer T-M, Hofer H, Schoeniger-Hekele M. Silibinin is a potent antiviral agent in patients with chronic HCV infection not responding to peginterferon/ribavirin therapy. Gastroenterology 2008; 134: 829 [Abstract W1002].
25. Bonifaz V SY, Lambrecht R, Donohue SE, Moschenross D, Bonkovsky HL. Silymarin down-regulates HCV core and up-regulates heme oxygenase-1 gene expression in the CNS3 replicon line of human liver cells. Hepatology 2007; 46: 363A, [Abstract 278].
26. Shibano M, Lin AS, Itokawa H, Lee KH. Separation and characterization of active flavonolignans of Silybum marianum by liquid chromatography connected with hybrid ion-trap and time-of-flight mass spectrometry (LC-MS/IT-TOF). J Nat Prod 2007; 70: 1424-8.
27. Dinev D, Jordan BW, Neufeld B, et al. Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. Eur Mol Biol Org Rep 2001; 2: 829-34.
28. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-3.
29. Flores KRH, Benner K. The use of naturopathic remedies for chronic liver diseases [letter]. Am J Gastroent 1996; 91: 2654-5.
30. Hoh C, Boocock D, Marczylo T, et al. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: Silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences. Clin Cancer Res 2006; 12: 2944-50.
31. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: Differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 2005; 65: 4448-57.
32. Singh RP, Mallikarjuna GU, Sharma G, et al. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin Cancer Res 2004; 10: 8641-7.
33. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci USA 2006; 103: 3805-9.
34. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Med 2005; 11: 791-6.
35. de Lucas S, Bartolome J, Carreno V. Hepatitis C virus core protein down-regulates transcription of interferon-induced antiviral genes. J Inf Dis 2005; 191: 93-9.
36. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: Possible implications for hepatitis C virus persistence. J Immunol 1999; 162: 931-8.
37. Ciccaglione AR, Stellacci E, Marcantonio C, et al. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 2007; 81: 202-14.
38. Basu A, Meyer K, Ray RB, Ray R. Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene. Virology 2001; 288: 379-90.
39. Bode JG, Ludwig S, Ehrhardt C, et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J 2003; 17: 488-90.
40. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. New Engl J Med 2006; 355: 2444-51.
41. Pan Y, Wei W, Kang L, et al. NS5A protein of HCV enhances HBV replication and resistance to interferon response. Biochem Biophys Res Commun 2007; 359: 70-5.
42. Aus dem Siepen M, Lohmann V, Wiese M, Ross S, Roggendorf M, Viazov S. Nonstructural protein 5A does not contribute to the resistance of hepatitis C virus replication to interferon alpha in cell culture. Virology 2005; 336: 131-6.
43. Martin D, Rojo AI, Salinas M, et al. Regulation of heme oxygenase-1 expression through the phosphatidylinositol 3-kinase/Akt pathway and the Nrf2 transcription factor in response to the antioxidant phytochemical carnosol. J Biol Chem 2004; 279: 8919-29.